Rupam Manna, Medical Oncologist, Entrepreneur, interested in Metabolism education and brain science, shared a post on X:
“Monitoring T-DXd:
Early Detection Saves Lives
Trastuzumab deruxtecan (T-DXd) has transformed the treatment of HER2-positive and HER2-low breast cancer, but interstitial lung disease (ILD)/pneumonitis remains its most important potentially fatal toxicity.
Key takeaways:
- Baseline clinical assessment + CT chest + ECHO + CBC/LFT/RFT
- Assess for cough, dyspnea, fever, and exercise tolerance at every 3-week cycle
- CT chest every 9–12 weeks (or earlier in selected patients) for ILD surveillance
- Any new respiratory symptom = hold T-DXd immediately and evaluate for ILD
- Early corticosteroids can prevent progression to severe or fatal pneumonitis
Remember:
Treat every new respiratory symptom in a patient receiving T-DXd as ILD until proven otherwise. Early recognition is the key to safer therapy and better outcomes.”
Other articles featuring Rupam Manna on OncoDaily.